Navigation Links
Step forward in foot-and-mouth disease understanding
Date:12/9/2011

Researchers at the University of Leeds have been studying an enzyme called 3D which plays a vital role in the replication of the virus behind the disease. They have found that this enzyme forms fibrous structures (or fibrils) during the replication process. What's more, they have found a molecule which can prevent these fibrils forming.

The project was funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and its findings have been published by the Journal of Virology.

"It's too much of a jump to say that we've found a potential drug target for treatment of foot-and-mouth disease because there's still such a lot we don't know," says Dr Nicola Stonehouse of the University of Leeds' Faculty of Biological Sciences. "However, we do think these findings are significant and provide us with a new avenue for exploration."

Foot-and-mouth is a one of the most readily transmissible diseases known to man, but the mechanisms by which it infects animals are not well understood. The virus responsible for the disease is able to reproduce very quickly, enabling it to cause widespread devastation in a short space of time. The 2001 outbreak in the UK resulted in the deaths of around seven million sheep and cattle at an extremely high cost to the British agricultural sector. Another, more contained outbreak, occurred in 2007.

In laboratory experiments, the research team were able to see that the 3D enzyme forms fibrils when it is copying genetic information it requires to replicate. The implications of these fibrils are not yet fully understood, but it is thought they may play an important role in the reproduction process. If this is the case, having already found a molecule to block the fibril formation could be significant.

"The next stage of our research will be to investigate these fibrils further, to look at their structure and purpose," says PhD student Kris Holmes, who has been working on the project.

Because FMD is classed as a dangerous pathogen, only one laboratory in the UK the Institute for Animal Health at Pirbright, in Surrey is licensed to work with the actual virus. In this research, the Leeds team used a simple, non-harmful model of the virus.


'/>"/>
Contact: Dr Nicola Stonehouse
n.j.stonehouse@leeds.ac.uk
44-113-343-3102
University of Leeds
Source:Eurekalert

Related biology news :

1. Stampede charges computational science forward in tackling complex societal challenges
2. Big steps forward in human functional brain imaging, but collaborations key to patient benefit
3. Hips take walking in stride; ankles put best foot forward in run
4. ONR, Marine Corps show alternative energy use at forward operating bases can save dollars, lives
5. Stroke research takes 2 steps forward
6. $1.6 million to take forward breakthrough research in heart disease
7. Growing drought-tolerant crops inching forward
8. CAKE offers way forward for climate change adaptation
9. A fat forward research tool
10. Meteosat Third Generation takes a step forward
11. First adhere, then detach and glide forward
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):
(Date:8/10/2017)... ... August 09, 2017 , ... The ... the clinic is here. The team at Capricor Therapeutics, Inc. utilized a cardiosphere-derived ... clinical studies. , Dr. Travis Antes, head of analytical development at Capricor ...
(Date:8/10/2017)... ... August 09, 2017 , ... Okyanos Center for Regenerative Medicine ... the Pelican Bay Hotel in Freeport, Grand Bahama on September 27, 2017. This daytime ... , With oversight from the Ministry of Health’s National Stem Cell Ethics Committee (NSCEC) ...
(Date:8/10/2017)... ... August 10, 2017 , ... DrugDev and the ... to demonstrate how Good Clinical Practice (GCP) can be used throughout the site ... webinar will discuss the importance of GCP compliance, how sites are affected by GCP ...
(Date:8/10/2017)... (PRWEB) , ... August 10, 2017 , ... ... the stock market news outlet had initiated coverage on Next Group Holdings, Inc. ... and underserved consumer markets geared toward those that cannot engage in traditional banking ...
Breaking Biology Technology: